GLPG3667
GLPG3667-CL-214
Phase 2 small_molecule completed
Quick answer
GLPG3667 for Dermatomyositis is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lakefront Biotherapeutics NV
- Indication
- Dermatomyositis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed